Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
TG Therapeutics, Inc is a biotechnology business based in the US. TG Therapeutics shares (TGTX) are listed on the NASDAQ and all prices are listed in US Dollars. TG Therapeutics employs 217 staff and has a trailing 12-month revenue of around USD$152,000.
|Latest market close||USD$29.52|
|52-week range||USD$6.34 - USD$31.97|
|50-day moving average||USD$28.4503|
|200-day moving average||USD$23.8092|
|Wall St. target price||USD$47.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.959|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||0.10%|
|1 month (2020-11-06)||4.64%|
|3 months (2020-09-04)||23.98%|
|6 months (2020-06-05)||61.49%|
|1 year (2019-12-05)||284.38%|
|2 years (2018-12-04)||490.40%|
|3 years (2017-12-05)||271.32%|
|5 years (2015-12-04)||109.07%|
|Gross profit TTM||USD$152,000|
|Return on assets TTM||-76.52%|
|Return on equity TTM||-318.55%|
|Market capitalisation||USD$3.6 billion|
TTM: trailing 12 months
There are currently 13.7 million TG Therapeutics shares held short by investors – that's known as TG Therapeutics's "short interest". This figure is 0.3% up from 13.7 million last month.
There are a few different ways that this level of interest in shorting TG Therapeutics shares can be evaluated.
TG Therapeutics's "short interest ratio" (SIR) is the quantity of TG Therapeutics shares currently shorted divided by the average quantity of TG Therapeutics shares traded daily (recently around 1.3 million). TG Therapeutics's SIR currently stands at 10.38. In other words for every 100,000 TG Therapeutics shares traded daily on the market, roughly 10380 shares are currently held short.
However TG Therapeutics's short interest can also be evaluated against the total number of TG Therapeutics shares, or, against the total number of tradable TG Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TG Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 TG Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1318% of the tradable shares (for every 100,000 tradable TG Therapeutics shares, roughly 132 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against TG Therapeutics.
Find out more about how you can short TG Therapeutics stock.
We're not expecting TG Therapeutics to pay a dividend over the next 12 months.
TG Therapeutics's shares were split on a 100:5625 basis on 30 April 2012. So if you had owned 5625 shares the day before before the split, the next day you'd have owned 100 shares. This wouldn't directly have changed the overall worth of your TG Therapeutics shares – just the quantity. However, indirectly, the new 5525% higher share price could have impacted the market appetite for TG Therapeutics shares which in turn could have impacted TG Therapeutics's share price.
Over the last 12 months, TG Therapeutics's shares have ranged in value from as little as $6.34 up to $31.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TG Therapeutics's is 2.2198. This would suggest that TG Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. is headquartered in New York, New York.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.